✨ Onyx Summary Geron Corporation issued 2026 financial guidance projecting RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million, reflecting expected commercial growth alongside reduced operating spend. The outlook underscores Geron’s focus on scaling RYTELO in lower-risk MDS, advancing its Phase 3 IMpactMF
✨ Onyx Summary Ocugen, Inc. reported publication in Nature Eye of positive 12-month Phase 1 GARDian1 trial results for OCU410ST, showing favorable safety and early efficacy signals in patients with Stargardt disease, including reduced atrophic lesion growth and stabilized or improved visual acuity versus untreated eyes. The data support advancement of
✨ Onyx Summary Ocugen, Inc. announced that CEO and co-founder Dr. Shankar Musunuri will present at the J.P. Morgan Healthcare Conference on January 15, 2026, highlighting progress across its modifier gene therapy platform and its roadmap toward multiple BLA filings beginning with OCU400 for retinitis pigmentosa. MALVERN, Pa., Jan. 09,
✨ Onyx Summary Perspective Therapeutics, Inc. reported updated interim Phase 1/2a data for its lead radiopharmaceutical [212Pb]VMT-α-NET in SSTR2-positive neuroendocrine tumors, showing no dose-limiting toxicities across 56 treated patients and encouraging anti-tumor activity at the 5.0 mCi dose. The results, presented at ASCO GI 2026, support continued dose
✨ Onyx Summary Foghorn Therapeutics Inc. outlined its 2026 strategic objectives, highlighting a $50 million equity financing that strengthens its balance sheet and supports advancement of its first-in-class oncology pipeline, including the ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers. The update underscored progress across partnered and proprietary degrader programs
✨ Onyx Summary Lexicon Pharmaceuticals, Inc. released a white paper summarizing insights from an October 2025 Washington, D.C. roundtable on chronic pain, highlighting the scale of unmet need and barriers to access for effective, non-opioid treatments. The publication aligns with recent U.S. Senate legislation aimed at expanding Medicare coverage
✨ Onyx Summary MassBio reported that Massachusetts biopharma companies grew their drug development pipeline by nearly 14% in 2025—more than double the national rate—despite venture capital falling to a six-year low and IPO markets remaining constrained. The data underscores the state’s continued strength in early-stage innovation, premium venture
✨ Onyx Summary Guardant Health, Inc. announced that its FDA-approved Shield blood test for colorectal cancer screening is now covered by TRICARE for active-duty service members and their families, with no copay for average-risk individuals aged 45 and older. The coverage expands access to the first FDA-approved blood-based primary screening option
✨ Onyx Summary Cellares and City of Hope will collaborate to evaluate automated manufacturing and quality control for City of Hope’s investigational CAR T therapy targeting glioblastoma at the preclinical stage. The effort aims to establish scalable, reproducible manufacturing processes for solid tumor CAR T programs, addressing a key bottleneck
FLORHAM PARK, N.J., Jan. 07, 2026 – Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,
✨ Onyx Summary Phathom Pharmaceuticals, Inc. announced plans for an underwritten public offering of common stock or pre-funded warrants, with an additional 30-day option for underwriters to purchase up to 15% more securities, subject to market conditions. Proceeds are expected to support general corporate purposes, including commercialization and R&D,
✨ Onyx Summary Phathom Pharmaceuticals, Inc. reported preliminary 2025 results showing approximately $175 million in full-year net revenue, fourth-quarter revenue of roughly $57–58 million, and over one million U.S. prescriptions dispensed for its lead product VOQUEZNA since launch. The company expects to reach operating profitability in the second half
✨ Onyx Summary Lexicon Pharmaceuticals, Inc. announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco. The presentation offers investors an opportunity to hear directly from leadership as Lexicon advances its pipeline across multiple therapeutic areas. THE WOODLANDS, TEXAS,
✨ Onyx Summary MassBio and the Kendall Square Association have formed a strategic partnership to expand member access, shared programming, and cross-sector engagement across the Kendall Square life sciences ecosystem. The collaboration positions the MassBioHub as a central convening space and reflects a broader effort to strengthen connectivity, inclusivity, and community
✨ Onyx Summary Autolus Therapeutics plc will evaluate the feasibility of Cellares Corp’ automated Cell Shuttle platform to potentially augment future commercial manufacturing capacity for its approved CAR T therapy AUCATZYL at its UK facility. The assessment reflects Autolus’ preparation for potential demand growth beyond current infrastructure and highlights industry efforts
ALISO VIEJO, Calif., Jan. 06, 2026 – SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development
![Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium](/content/images/size/w1304/format/webp/2026/01/Perspective.png)
